Estrella Immunopharma received a notice on April 30, 2025, indicating non-compliance with Nasdaq's minimum bid price rule. The company's common stock had traded below the $1.00 per share threshold for 30 consecutive business days.
This notice requires Estrella to regain compliance by October 27, 2025. Failure to meet this requirement could result in the delisting of its common stock from Nasdaq.
Delisting would significantly impact the company's liquidity and its ability to raise necessary capital for ongoing operations and clinical trials. This situation adds pressure to the company's already precarious financial position.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.